A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： Xiaodong,Liu

第一单位： Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

作者： Xiaodong,Liu ^[1] ; Weipeng,Zhao ^[1] ; Yongsheng,Jia ^[1] ; Yehui,Shi ^[1] ; Xu,Wang ^[1] ; Shufen,Li ^[1] ; Pin,Zhang ^[2] ; Chen,Wang ^[1] ; Chunfang,Hao ^[1] ; Zhongsheng,Tong ^[3]

作者单位： Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. ^[1] Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. ^[2] Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, West Huan-Hu Road, Ti Yuan Bei, Hexi District, Tianjin 300060, China. ^[3]

关键词 chemotherapy gemcitabine plus capecitabine gemcitabine plus carboplatin triple-negative breast cancer tumor-infiltrating lymphocytes

DOI 10.1177/17588359241240304

PMID 39634173

发布时间 2024-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Therapeutic advances in medical oncology

2024年16卷

17588359241240304页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A non-inferiority, phase III trial of gemcitabine plus capecitabine <i>versus</i> gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除